JP2021512142A5 - - Google Patents

Info

Publication number
JP2021512142A5
JP2021512142A5 JP2020560590A JP2020560590A JP2021512142A5 JP 2021512142 A5 JP2021512142 A5 JP 2021512142A5 JP 2020560590 A JP2020560590 A JP 2020560590A JP 2020560590 A JP2020560590 A JP 2020560590A JP 2021512142 A5 JP2021512142 A5 JP 2021512142A5
Authority
JP
Japan
Prior art keywords
seq
peptide
influenza hemagglutinin
antigen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020560590A
Other languages
English (en)
Japanese (ja)
Other versions
JP7542257B2 (ja
JP2021512142A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/051853 external-priority patent/WO2019145475A2/en
Publication of JP2021512142A publication Critical patent/JP2021512142A/ja
Publication of JP2021512142A5 publication Critical patent/JP2021512142A5/ja
Priority to JP2024134738A priority Critical patent/JP2024160341A/ja
Application granted granted Critical
Publication of JP7542257B2 publication Critical patent/JP7542257B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020560590A 2018-01-25 2019-01-25 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法 Active JP7542257B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024134738A JP2024160341A (ja) 2018-01-25 2024-08-13 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18153348.0 2018-01-25
EP18153348 2018-01-25
PCT/EP2019/051853 WO2019145475A2 (en) 2018-01-25 2019-01-25 Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024134738A Division JP2024160341A (ja) 2018-01-25 2024-08-13 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法

Publications (3)

Publication Number Publication Date
JP2021512142A JP2021512142A (ja) 2021-05-13
JP2021512142A5 true JP2021512142A5 (enExample) 2022-02-01
JP7542257B2 JP7542257B2 (ja) 2024-08-30

Family

ID=61192649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560590A Active JP7542257B2 (ja) 2018-01-25 2019-01-25 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法
JP2024134738A Pending JP2024160341A (ja) 2018-01-25 2024-08-13 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024134738A Pending JP2024160341A (ja) 2018-01-25 2024-08-13 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法

Country Status (6)

Country Link
US (2) US12239736B2 (enExample)
EP (1) EP3743101A2 (enExample)
JP (2) JP7542257B2 (enExample)
CN (1) CN111954541A (enExample)
BR (1) BR112020013405A2 (enExample)
WO (1) WO2019145475A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104936579B (zh) * 2012-11-19 2020-02-07 新加坡科技研究局 用于引发对免疫原的免疫响应的方法
BR112022001185A2 (pt) * 2019-08-01 2022-03-15 Acm Biolabs Pte Ltd Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
US11642407B2 (en) * 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
WO2021214339A2 (en) 2020-04-24 2021-10-28 Acm Biolabs Pte Ltd Vaccine against human-pathogenic coronaviruses
JP2024500360A (ja) * 2020-12-11 2024-01-09 エイシーエム バイオラブズ プライベート リミテッド 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法
CN117597109A (zh) * 2021-02-02 2024-02-23 Acm 生物实验室私人有限公司 聚合物囊泡相关联的佐剂用于刺激免疫应答的单独使用
AU2022258552A1 (en) * 2021-04-12 2023-10-19 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
CN113416788B (zh) * 2021-07-14 2022-04-29 兰州大学 一种与湖羊睾丸性状相关的adpgk基因分子标记及其应用
US20250295762A1 (en) * 2022-03-21 2025-09-25 The University Of North Carolina At Chapel Hill Composite bioactive compositions and applications thereof
WO2024081641A2 (en) * 2022-10-10 2024-04-18 Northwestern University Methods for preparing protein-conjugated nanocarriers
CN117045809B (zh) * 2023-09-27 2025-08-29 国家纳米科学中心 异种哺乳动物细胞来源的囊泡在制备疫苗载体中的应用
CN120860194A (zh) * 2025-07-15 2025-10-31 中国人民解放军总医院第一医学中心 一种流感病毒纳米疫苗及其制备方法与应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US569825A (en) 1896-10-20 John h
US633425A (en) 1899-01-26 1899-09-19 Louis Henry Clyborne Wire-tightener.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
WO2005018610A1 (en) * 2003-08-21 2005-03-03 Lipotek Pty Ltd In vivo targeting of dendritic cells
AU2007319836A1 (en) * 2006-11-14 2008-05-22 The Trustees Of The University Of Pennsylvania Efficient nuclear delivery of antisense oligonucleotides
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
EP2601262A4 (en) * 2010-08-05 2014-01-22 Agency Science Tech & Res VESIGN STRUCTURE WITH SEVERAL CHAMBERS AND METHOD FOR THEIR EDUCATION
EP4218808A3 (en) 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvant and vaccine compositions
CN104936579B (zh) * 2012-11-19 2020-02-07 新加坡科技研究局 用于引发对免疫原的免疫响应的方法
US10017545B2 (en) * 2013-06-03 2018-07-10 University Of Maryland, College Park Compositions and vaccines comprising vesicles and methods of using the same
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
WO2016055611A1 (en) * 2014-10-09 2016-04-14 Universität Basel Self-assembled nanostructures and methods of use thereof
US9636397B2 (en) 2015-03-24 2017-05-02 VaxLiant, LLC Adjuvant compositions and related methods
CA3016457A1 (en) * 2016-03-02 2017-09-08 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy

Similar Documents

Publication Publication Date Title
JP2021512142A5 (enExample)
CN108743939B (zh) 共载抗原、mpla与imq的阳离子磷脂-聚合物杂化纳米粒疫苗佐剂及制备方法与应用
Zhu et al. Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination
Bonifaz et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination
US20220273792A1 (en) A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes
Shahiwala et al. Nanocarriers for systemic and mucosal vaccine delivery
JP6443646B2 (ja) Ｐｅｇ化リン脂質を担体とするポリペプチドワクチンミセル
Joshi et al. Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles
Sunoqrot et al. Lipid-and polymer-based nanocarrier platforms for cancer vaccine delivery
CN113476598A (zh) 一种新型冠状病毒亚蛋白纳米疫苗及其制备方法和应用
CN116603068B (zh) 一种多肽疫苗递送载体及其制备方法
Li et al. The finely regulating well-defined functional polymeric nanocarriers for anti-tumor immunotherapy
US20230398207A1 (en) Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
JP2024518710A5 (enExample)
CN105194663A (zh) 聚乙二醇化磷脂为载体的胶束多肽疫苗
Singh et al. Applications of nanotechnology in vaccine delivery
US20040126421A1 (en) Liposomal system and method of using same
AU2022216818A9 (en) Sole use of polymersome associated adjuvant for stimulating an immune response
Savla et al. Nanoparticles in the development of therapeutic cancer vaccines
Brown et al. Nucleic Acids as Adjuvants
CN120189518A (zh) 疫苗载体组合物、纳米疫苗药物组合物、疫苗制剂及其制备方法
이혜선 Development of adjuvants using cytokine and polymeric particles for efficient mucosal immunization
Sahu et al. Nanoparticulate Vaccines: Mechanistic Insight and Recent Advances
Chesson Supramolecular Peptide Nanofiber Vaccines for Eliciting CD8+ T-cell Responses
TW202444409A (zh) 組成物、疫苗及a型流感的治療方法